These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 18333902

  • 1. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
    Ball NJ, Cowan BJ, Moore GR, Hashimoto SA.
    J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
    [Abstract] [Full Text] [Related]

  • 2. Contribution of endermology to improving indurations and panniculitis/lipoatrophy at glatiramer acetate injection site.
    Rubio Fernández D, Rodríguez Del Canto C, Marcos Galán V, Falcón N, Edreira H, Sevane Fernández L, Francoli Martínez P, Sánchez-De la Rosa R.
    Adv Ther; 2012 Mar; 29(3):267-75. PubMed ID: 22382874
    [Abstract] [Full Text] [Related]

  • 3. Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study.
    Soares Almeida LM, Requena L, Kutzner H, Angulo J, de Sa J, Pignatelli J.
    J Am Acad Dermatol; 2006 Dec; 55(6):968-74. PubMed ID: 17097393
    [Abstract] [Full Text] [Related]

  • 4. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.
    Soós N, Shakery K, Mrowietz U.
    Am J Clin Dermatol; 2004 Dec; 5(5):357-9. PubMed ID: 15554737
    [Abstract] [Full Text] [Related]

  • 5. Endermology: a treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate.
    Lebrun C, Mondot L, Bertagna M, Calleja A, Cohen M.
    Clin Neurol Neurosurg; 2011 Nov; 113(9):721-4. PubMed ID: 21839580
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report.
    Hashimoto S, Ball Nj, Tremlett H.
    Mult Scler; 2009 Apr; 15(4):521-2. PubMed ID: 19091880
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Contact dermatitis induced by glatiramer acetate.
    Haltmeier S, Yildiz M, Müller S, Anliker MD, Heinzerling L.
    Mult Scler; 2011 Nov; 17(11):1390-2. PubMed ID: 21729979
    [Abstract] [Full Text] [Related]

  • 12. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M, 9006 Study Group.
    Neurology; 2007 Mar 20; 68(12):939-44. PubMed ID: 17372130
    [Abstract] [Full Text] [Related]

  • 13. Glatiramer acetate-induced lobular panniculitis and skin necrosis.
    Watkins CE, Litchfield J, Youngberg G, Leicht SS, Krishnaswamy G.
    Cutis; 2015 Mar 20; 95(3):E26-30. PubMed ID: 25844792
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Glatiramer: new preparation. No place in multiple sclerosis.
    Prescrire Int; 2004 Feb 20; 13(69):10-2. PubMed ID: 15055208
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.